CRL Stock Recent News
CRL LATEST HEADLINES
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--The Charles River Incubator Program announces its first cohort, expediting the development of technologies and life-changing therapies for patients.
CRL's first-quarter 2025 performance is expected to have been hurt by a challenging biopharmaceutical environment.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Ahead of AACR 2025, Charles River announces updates to its comprehensive portfolio to support the discovery and development of novel oncology drugs.
Aldeyra Therapeutics' stock offers a compelling contrarian opportunity, rebounding 70% after a 75% drop due to an FDA CRL for Reproxalap in dry eye disease. The FDA requested additional efficacy data. Aldeyra already has two trials with data expected in Q2 2025, aiming for NDA resubmission by mid-2025. Reproxalap targets upstream inflammation, offering rapid symptom relief in a large market, with a risk-adjusted U.S. revenue potential of $216 million annually.
It's been a turbulent start to 2025 for investors. The market has faced a wave of selling pressure driven by surging tariffs, escalating geopolitical tensions, and growing fears of a global economic slowdown.
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules first-quarter 2025 earnings release and conference call.
Charles River (CRL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Aldeyra Therapeutics' stock plummeted 74% due to an FDA Complete Response Letter for reproxalap but presents a favorable risk-reward for speculative investors. Despite past setbacks, ALDX's history of resilience and upcoming trial results offer potential catalysts for recovery, with minimal near-term dilution risk. ALDX's strong cash position and reduced burn rate provide a safety net, with significant upside potential if reproxalap trials succeed and FDA approval is achieved.